Listen
Reason for request
Inclusion for two extensions of the indication.
-
Clinical Benefit
| Substantial |
Substantial AB |
Clinical Added Value
| no clinical added value |
In the absence of a comparative study versus ERBITUX, VECTIBIX does not provide an improvement in actual benefit (non-existent IAB, V) in the treatment of wild-type KRAS metastatic colorectal cancer : - in first-line in combination with FOLFOX, - in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). |
English version
Contact Us
Évaluation des médicaments
